Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ibuprofen 400 mg/10 mL Oral Suspension vs. MOMENTACT Tablet
NCT02902302Phase 1Completed
- Sponsor
- Angelini Pharma
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuprofen in pain, fever and inflammation (2 arms), sponsored by Angelini Pharma. Primary endpoints: Peak Plasma Concentration of (S)-ibuprofen and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration for (S)-ibuprofen. Started May 2016; status: completed.
02
Drugs
ibuprofen
03
Conditions
painfeverinflammation
Beyond the preview
Go deeper on NCT02902302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902302.